Sun Pharma receives USFDA’s nod to sell a drug to treat Osteoporosis: Report

19 Feb 2014 Evaluate

Sun Pharmaceutical Industries has been reported to have received US Food and Drug Administration (USFDA)’s approval to sell a drug to treat Osteoporosis, a bone-weakening disease. Currently the drug, Ibandronate Sodium, is marketed by Roche under the brand name Bovina.

Bovina generated annual sales of $82 million in 2012. Further, Sun pharma is the only generic player to have final approval for this product as many other players would be able to sell the drug after its patent expiry on September 2, 2014.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1631.65 -2.75 (-0.17%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×